Drug Trial Radar · NCT07840820
Phase II/III Study of FXS5626 in Participants With Non-segmental Vitiligo
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Nov 10, 2027
Study completion Dec 8, 2027
Sponsor
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, adaptive seamless design, Phase II/III study evaluating the efficacy and safety of FXS5626 in participants with non-segmental vitiligo.
Conditions
- Non-segmental Vitiligo
Interventions
Intervention1: FXS5626 TabletsDrug
FXS5626 tablets administered orally twice daily (BID) for 24 weeks.
Intervention2: FXS5626 TabletsDrug
FXS5626 tablets administered orally twice daily (BID) for 24 weeks.
Intervention3: FXS5626 TabletsDrug
FXS5626 tablets administered orally twice daily (BID) for 24 weeks.
Intervention4: FXS5626 TabletsDrug
FXS5626 tablets administered orally twice daily (BID) for 52 weeks.
Intervention5: FXS5626 Placebo TabletsDrug
FXS5626 placebo tablets administered orally twice daily (BID) for 24 weeks.
Intervention6: FXS5626 Placebo TabletsDrug
FXS5626 placebo tablets administered orally twice daily (BID) for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in facial vitiligo area scoring index (F-VASI) at week 24 in Phase 2 study.Time frame: 24 weeks
- Proportion of participants achieving Facial Vitiligo Area Scoring Index 75 (F-VASI 75, at least 75% improvement from baseline) at Week 52 in Phase 3 study.Time frame: 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.